Home

EDV
EDV
Covid EDV Vax Booster_Immune_compromised
COVID-19 Vaccine Trial for Immune-Compromised People

We are looking for volunteers who:
• are 18 years and older
• are immune-compromised/suppressed
• have been vaccinated or recovered from COVID-19 at least 3 months prior

For more information, please contact our Clinical Trials Team

For more information
MORE INFO
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal

The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023).

You can view the publication here. 

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology